利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.018 秒)

    FUSED RING THROMBIN RECEPTOR ANTAGONISTS
    1.
    发明授权
    FUSED RING THROMBIN RECEPTOR ANTAGONISTS 有权
    简明RINGTHROMBINREZEPTOR拮抗剂

    公开(公告)号：EP2007755B1

    公开(公告)日：2012-06-27

    申请号：EP07775221.0

    申请日：2007-04-11

    申请人： Schering Corporation

    发明人： XIA, Yan ,  CHELLIAH, Mariappan, V. ,  CHACKALAMANNIL, Samuel

    IPC分类号： C07D405/06 ,  A61K31/443 ,  A61P7/02

    CPC分类号： C07D405/06 ,  C07D498/04

    摘要： Fused-ring, heterocyclic-substituted tricyclics of the Formula (I) or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein Formula (II) represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    SUBSTITUTED BICYCLIC AND TRICYCLIC THROMBIN RECEPTOR ANTAGONISTS
    4.
    发明公开
    SUBSTITUTED BICYCLIC AND TRICYCLIC THROMBIN RECEPTOR ANTAGONISTS 有权
    取代的二环和三环凝血酶受体拮抗剂

    公开(公告)号：EP2032560A1

    公开(公告)日：2009-03-11

    申请号：EP07796505.1

    申请日：2007-06-27

    申请人： Schering Corporation

    发明人： CHELLIAH, Mariappan, V. ,  CHACKALAMANNIL, Samuel ,  XIA, Yan

    IPC分类号： C07D405/06 ,  A61K31/443 ,  A61P7/02 ,  A61P35/00

    CPC分类号： C07D405/06

    摘要： Substituted bicyclic and tricyclic modified himbacine derivative of the formula (I) : or a pharmaceutically acceptable salt or solvate of said compound wherein (DU) represents an optional double bond and wherein En, Fn, Gn, Zn, Jn, X, R3, R9, R10, R11, R32, R33, B and Het are herein defined are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other agents is also claimed.

    THROMBIN RECEPTOR ANTAGONISTS
    5.
    发明公开
    THROMBIN RECEPTOR ANTAGONISTS 审中-公开
    THROMBIN受体拮抗剂

    公开(公告)号：EP1802609A2

    公开(公告)日：2007-07-04

    申请号：EP05802841.6

    申请日：2005-10-05

    申请人： SCHERING CORPORATION

    发明人： CHACKALAMANNIL, Samuel ,  CHELLIAH, Mariappan, V. ,  XIA, Yan ,  EAGEN, Keith, A.

    IPC分类号： C07D405/06 ,  C07D409/14 ,  C07D491/10 ,  C07D413/14 ,  C07D405/14 ,  A61K31/443 ,  A61P7/00

    CPC分类号： C07D405/06 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D491/10

    摘要： Heterocyclic-substituted tricyclics of the formula (I) or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein ---- represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A, B, G, M, X, J, n, Het, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    摘要翻译： 式（I）的杂环取代的三环或所述化合物，异构体或外消旋混合物的药学上可接受的盐或溶剂合物，其中----代表任选的双键，虚线任选为键或无键，产生 如化合价要求所允许的，并且其中A，B，G，M，X，J，n，Het，R 3，R 10，R 11，R 32和R 33在本文中定义并且其余取代基如定义 在说明书中公开了以及含有它们的药物组合物以及通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症有关的疾病的方法。 本发明还要求与其他心血管药物组合治疗。

    BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS
    6.
    发明公开
    BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS 有权
    二环和三环衍生物作为凝血酶受体拮抗剂

    公开(公告)号：EP2069326A2

    公开(公告)日：2009-06-17

    申请号：EP07867202.9

    申请日：2007-10-02

    申请人： Schering Corporation

    发明人： CHACKALAMANNIL, Samuel ,  CHELLIAH, Mariappan, V. ,  WANG, Yuguguang ,  XIA, Yan

    IPC分类号： C07D401/06 ,  C07D417/06 ,  A61K31/443 ,  A61P7/00

    CPC分类号： C07D401/06 ,  C07D417/06

    摘要： Heterocyclic-substituted tricyclics of the formula (I) or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    HIMBACINE ANALOGUES AS THROMBIN RECEPTOR ANTAGONISTS
    8.
    发明公开
    HIMBACINE ANALOGUES AS THROMBIN RECEPTOR ANTAGONISTS 有权
    氨基胍类似物作为血栓素受体拮抗剂

    公开(公告)号：EP1436298A1

    公开(公告)日：2004-07-14

    申请号：EP02801732.5

    申请日：2002-10-16

    申请人： SCHERING CORPORATION

    发明人： CHACKALAMANNIL, Samuel ,  CHELLIAH, Mariappan, V. ,  CLASBY, Martin, C. ,  XIA, Yan

    IPC分类号： C07D491/04 ,  A61K31/445 ,  A61K31/34 ,  A61P29/00 ,  A61P19/02 ,  A61P9/00

    CPC分类号： C07D491/04 ,  C07D493/04 ,  C07D495/04

    摘要： Heterocyclic-substituted tricyclics of the formula (I) or a pharmaceutically acceptable salts thereof, wherein: n1 and n2 are independently 0-2; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is alkyl or optionally substituted alkenyl; R22 is -COR23 or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative; R23 is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or -COOH and/or -SO¿3?H substituted alkyl; R?1, R2, R3, R9, R10 and R11¿ are as defined in the specification; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.

    摘要翻译： 式（I）的杂环取代的三环或其药学上可接受的盐，其中：n1和n2独立地为0-2; Het是任选取代的单环，双环或三环杂芳族基团; B是烷基或任选取代的链烯基; R22是-COR23或羧基，亚磺酰基，磺酰基，磺酰胺或氨基酸衍生物; R23是卤代烷基; 烯基; 卤代链; 炔基; 任选取代的环烷基 环烷基 - 烷基; 芳基; 芳; 杂; 杂环; 或-COOH和/或-SO 3 H取代的烷基; R 1，R 2，R 3，R 9，R 10和R 11如说明书中所定义; 以及含有它们的药物组合物以及通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病的方法。

    HIMBACINE ANALOGUES AS THROMBIN RECEPTOR ANTAGONISTS
    10.
    发明授权
    HIMBACINE ANALOGUES AS THROMBIN RECEPTOR ANTAGONISTS 有权
    HIMBACINANALOGA ALS THROMBINREZEPTORANTAGONISTEN

    公开(公告)号：EP1436298B1

    公开(公告)日：2011-09-21

    申请号：EP02801732.5

    申请日：2002-10-16

    申请人： Schering Corporation

    发明人： CHACKALAMANNIL, Samuel ,  CHELLIAH, Mariappan, V. ,  CLASBY, Martin, C. ,  XIA, Yan

    IPC分类号： C07D491/04 ,  A61K31/445 ,  A61K31/34 ,  A61P29/00 ,  A61P19/02 ,  A61P9/00

    CPC分类号： C07D491/04 ,  C07D493/04 ,  C07D495/04

    摘要： Heterocyclic-substituted tricyclics of the formula (I) or a pharmaceutically acceptable salts thereof, wherein: n1 and n2 are independently 0-2; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is alkyl or optionally substituted alkenyl; R22 is -COR23 or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative; R23 is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or -COOH and/or -SO¿3?H substituted alkyl; R?1, R2, R3, R9, R10 and R11¿ are as defined in the specification; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.